Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03547986
Other study ID # C1706
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date November 9, 2018
Est. completion date March 2024

Study information

Verified date August 2022
Source Biotronik AG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Both drug-coated balloon and stents have been used for a number of years to treat subjects with Peripheral Artery Disease (PAD) and are recognized as very good treatment methods. However, due to a higher risk of blood clot formation, requiring a longer anticoagulant treatment, and the challenge of treating re growth of tissue extending through the metal mesh of the stent, the physicians try to reserve stent placement to situation where it's really needed, in case of flow-limiting vessel dissection or acute re-narrowing. The purpose of this study is to evaluate the utility of several procedural diagnostic techniques in helping the physicians to better decide whether a stent is needed or not. The study will also estimate the safety and efficacy of Passeo-18 Lux drug-coated balloon associated to Pulsar 18 bare metal stent when and where needed to treat PAD


Description:

The REACT treatment concept aims at minimizing the metal burden, combining Passeo-18 Lux Drug-Coated Balloon (DCB) with Pulsar-18 thin struts bare metal stent, as low as reasonably achievable (ALARA), while benefiting from the antirestenotic properties of Paclitaxel. However, in order to optimally apply this selective stenting approach, it is needed to clearly identify when a stent is indicated. Angiographic images, even with additional projections, are sometimes insufficient to clearly determine if a dissection is flow-limiting and the subsequent stent requirement. There is currently no definition nor validated method to define flow-limiting dissection in the peripheral arteries. Even though it has been widely used, the classification developed by the National Heart, Lung, and Blood Institute to grade coronary artery dissection as A to F19, based on angiographic appearance cannot be extrapolated to peripheral arteries. Therefore, the purpose of the study is to evaluate the incremental value of several adjunctive procedural assessments to standard angiography to identify flow-limiting dissection and residual stenosis, and better inform the operator on the stent requirement. In addition, the study will evaluate the safety and efficacy of the REACT algorithm.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 150
Est. completion date March 2024
Est. primary completion date January 3, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject has provided written informed consent before any study specific test or procedure and is willing and able to comply with the required follow-up visits and procedures - Subject has a chronic, symptomatic lower limb ischemia defined as Rutherford categories 2 to 4 Angiographic criteria: - Single lesion or consecutive single lesions with a healthy segment(s) of = 2cm in-between - De novo, restenotic or (re)occluded lesion(s) post Percutaneous Transluminal Angioplasty in the native superficial femoral artery (SFA) and or the proximal popliteal artery (PPA) - Lesion(s) must be located at least 1 cm distal to the profunda femoris artery and at least 3 cm above the knee joint (radiographic joint space) - Degree of stenosis =70% by visual angiographic assessment - Vessel diameter = 4 and = 7 mm - Patent inflow artery, free from significant lesion (>50%) as confirmed by angiography. Treatment of the target lesion is acceptable after successful treatment of inflow iliac and/or common femoral artery lesion. The inflow lesion cannot be treated with a DCB or a Drug Eluting Stent - Patent infrapopliteal and popliteal artery, i.e., single vessel runoff or better with at least one of the three vessels patent (<50% stenosis) to the ankle or foot with no planned intervention Exclusion Criteria: - Previously stented target lesion - Target lesion/ previously treated with drug-coated balloon <12 months prior to enrollment. - Use of atherectomy, laser or other debulking devices in the target SFA/PPA vessel during the index procedure. - Failure to cross the target lesion with the guide wire - Presence of a complication following pre-dilation of target lesion, which in the opinion of the investigator would not allow the procedure to be performed in accordance with the REACT approach - Presence of aneurysm in the target vessel. - Prior on planned major amputation (above the ankle) in the target limb - Acute ischemia and/or acute thrombosis of the target SFA/PPA vessel prior to enrollment. - Perforation of the target vessel as evidenced by extravasation of contrast media prior to enrollment - Known hypersensitivity or contraindication to contrast media that, in the opinion of the investigator, cannot be adequately pre-medicated - Known hypersensitivity/allergy to Paclitaxel or other components of the investigational devices and comparator (e.g., nitinol, amorphous silicon carbide, polymer) - Known hypersensitivity or contraindication to antiplatelet, anticoagulant, thrombolytic medications that would be administered during the study - Subject with uncorrected bleeding disorders - Subject with renal failure - Life expectancy less than 12 months due to other comorbidities, that in the investigators opinion, could limit subject ability to comply with the study required follow-up visits/procedure and threaten the study scientific integrity - Pregnant, breast feeding, or plan to become pregnant in the next 12 months. - Current participation in another investigational drug or device clinical study that has not completed the primary endpoint at the time of enrollment or that upon investigator judgment could clinically interferes with the current study endpoints

Study Design


Intervention

Diagnostic Test:
Duplex Ultrasound (DUS)
Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Duplex Ultrasound
IVUS with Intraarterial pressure measurement (IAP) if needed
Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Intra-vascular ultrasound associated to Intraarterial pressure measurement if needed

Locations

Country Name City State
Australia Royal Perth Hospital Perth Western Australia
Austria Medical University Graz Graz
Austria Medizinische Universität Wien Vienna
Belgium OLV Ziekenhuis Aalst
Belgium A.Z. Sint-Blasius Dendermonde
Belgium AZ Groeninge Kortrijk
France CHU de Nantes Nantes
France Hopital Paris Saint Joseph Paris
Germany Karolinen-Hospital, Klinikum Arnsberg Arnsberg
Germany Universitäts-Herzzentrum Freiburg • Bad Krozingen Bad Krozingen
Germany SRH Klinikum Karlsbad-Langensteinbach Biederbach Baden-Wurttemberg
Germany Universitätsklinikum Leipzig Leipzig
Germany Universitätsklinikum Tübingen
Germany GRN Hospital Weinheim
Spain Hospital General de Guadalajara Guadalajara

Sponsors (1)

Lead Sponsor Collaborator
Biotronik AG

Countries where clinical trial is conducted

Australia,  Austria,  Belgium,  France,  Germany,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary diagnostic accuracy of duplex ultrasound specificity and sensitivity of duplex ultrasound combined to angiography vs angiography alone during index procedure
Secondary diagnostic accuracy of intraarterial pressure measurement specificity and sensitivity of intraarterial pressure measurement combined to angiography vs angiography alone during index procedure
Secondary diagnostic accuracy of intraarterial pressure measurement with IVUS specificity and sensitivity of intraarterial pressure measurement with IVUS combined to angiography vs angiography alone during index procedure
Secondary Target lesion stenting rate during index procedure
Secondary Number of stents used per target lesion during index procedure
Secondary Average stent length per target lesion during index procedure
Secondary Average target lesion length stented (full, spot) during index procedure
Secondary DCB technical success Delivery and successful use of Passeo-18 Lux DCB to the target lesion to achieve a residual stenosis no greater than 30% in the absence of flow-limiting dissection during index procedure
Secondary Stent technical success delivery and successful use of Pulsar-18 to the target lesion to achieve a residual stenosis no greater than 30% during index procedure
Secondary Procedural success technical success and no MAEs before discharge during index procedure
Secondary Primary Patency Primary patency is defined as DUS peak systolic velocity ratio (PSVR) =2.5 at the target lesion, in the absence of clinically driven Target Lesion Revascularization (cd TLR). 1, 6 and 12 months post index procedure
Secondary Major Adverse Event (MAE) Major adverse event (MAE) is defined as device or procedure related death within 30 days post index procedure, major target limb amputation or cd TLR post index procedure 1, 6 and 12 months post index procedure
Secondary Major Adverse Cardiac Event (MACE) Major adverse Cardiac event (MACE) is defined as death all causes, myocardial infarction, stroke, death or major amputation 1, 6 and 12 months post index procedure
Secondary Major Adverse Limb Event (MALE) Major adverse limb event (MALE) is defined as severe limb ischemia leading to an intervention or major vascular amputation 1, 6 and 12 months post index procedure
Secondary Clinically driven Target Lesion Revascularization Clinical Event Committee adjudicated TLR =Any post index procedure surgical or percutaneous intervention to the target lesion plus 5 mm proximal and distal to the stented lesion edge when a stent is used 1, 6, 12, 24 and 36 months post index procedure
Secondary Major target limb amputation rate 1, 6, 12, 24 and 36 months post index procedure
Secondary all cause of death rate 1, 6, 12, 24 and 36 months post index procedure
Secondary Hemodynamic improvement change in Ankel Brachial Index at 1, 6 and 12 months post index procedure compared to baseline 1, 6 and 12 months post index procedure
Secondary Rate of primary sustained clinical improvement Improvement in Rutherford Classification of at least one category for claudicants and by wound-healing and resting pain resolution for critical limb ischemia as compared to pre-procedure without the need for repeat TLR 1, 6 and 12 months post index procedure
Secondary Rate of secondary sustained clinical improvement Improvement in Rutherford Classification of at least one category for claudicants and by wound-healing and resting pain resolution for critical limb ischemia as compared to pre-procedure including the need for repeat TLR 1, 6 and 12 months post index procedure
Secondary Health Related Quality of Life The Euroquol Group 5 dimension quality of life questionnaire (EQ-5D) is a descriptive system comprising 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The results in a 1-digit number expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes patient's health state.
The EQ Visual Analogue Scale records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement
baseline, 1, 6 and 12 months post index procedure
Secondary Walk Impairment The Walk Impairment Questionnaire (WIQ) measure measures self-reported walking distance, walking speed, and stair-climbing ability baseline, 1, 6 and 12 months post index procedure
Secondary Resource utilisation Costs will be evaluated using specific information on resource use during index procedure, 12 month
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Completed NCT02022423 - Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease N/A